Acral lentiginous melanoma
MONDO:0003865A form of melanoma occurring most often on the plantar, palmar, subungual, and periungual skin. It presents as a pigmented macular lesion with irregular borders. Morphologically, it consists of atypical spindled and dendritic melanocytes. The epidermis is often hyperplastic and there is pagetoid infiltration of the epidermis by anaplastic cells.
Also known as: acral lentiginous malignant melanoma, acral lentiginous melanoma, acral lentiginous melanoma (disease), acral lentiginous melanoma, malignant, acral lentiginous melanoma, malignant (morphologic abnormality), ALM, acral lentiginous malignant melanoma of skin, acral melanoma
2783 clinical trials for this condition and its sub-types, 17 tagged with Acral lentiginous melanoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New STING agonist drug enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests the safety of CRD3874-SI, a drug that activates the STING pathway to boost the immune system against cancer. About 81 adults with advanced solid tumors (sarcoma, Merkel cell carcinoma, and others) will receive weekly IV infusions at increasing doses. …
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
Promising new combo tackles melanoma brain metastases in phase 2 trial
Disease control Recruiting nowThis phase 2 trial compares two treatment combinations for people with BRAF-V600 mutant melanoma that has spread to the brain. One group gets a targeted therapy (encorafenib and binimetinib) plus an immunotherapy (nivolumab), while the other gets two immunotherapies (ipilimumab a…
Phase 2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
BioNTech launches trial of BNT326 for advanced cancers
Disease control Recruiting nowThis study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Custom-Made vaccine trains immune system to fight advanced cancers
Disease control Recruiting nowThis early-phase trial is testing a personalized vaccine made from each patient's unique tumor mutations. The vaccine is given along with an immune booster (poly ICLC) to help the body's T cells attack the cancer. The study includes up to 25 adults with advanced melanoma, breast …
Phase 1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Supercharged immune cells take on advanced melanoma
Disease control Recruiting nowThis study tests a personalized treatment for advanced melanoma using a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), which are boosted with a protein called CD40L. After a short course of chemotherapy to make room, the enhanced cells are infused back a…
Phase 1/2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer, and give them back after a short course of chemotherapy. T…
Phase 1 • Sponsor: Anusha Kalbasi • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Morning vs. evening: can timing boost melanoma treatment?
Disease control Recruiting nowThis study tests whether giving standard immunotherapy drugs (ipilimumab and nivolumab) in the morning works better than giving them later in the day for people with advanced melanoma that has spread or cannot be removed. About 99 adults with stage IV melanoma will be randomly as…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Blood tests could predict melanoma treatment success
Knowledge-focused Recruiting nowThis study enrolls 200 people with acral or cutaneous melanoma who are starting standard immunotherapy. Researchers will collect blood samples every 3 weeks and tumor tissue after about 3 months of treatment. By analyzing circulating tumor cells, DNA, and other markers, they aim …
Sponsor: Xijing Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC